• Emergency uses of the vaccine have not been approved or licensed by the FDA, but have been authorized by the FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19). The Moderna COVID-19 Vaccine is authorized in individuals 6 months of age and older as a primary series. The Moderna COVID-19 Vaccine, Bivalent is authorized as a booster dose in individuals 18 years of age and older.

  • The EUA for these products is in effect for the duration of the COVID-19 EUA declaration justifying emergency use of the product, unless the declaration is terminated or the authorization is revoked sooner.

  • For more information on the EUA authorized uses of the vaccine, refer to the Fact Sheets for Healthcare Providers Administering Vaccine (Vaccine Providers) and Full Prescribing Information.

Sign up to receive updates from Moderna

Resources for Your Practice

Videos

What is the
mRNA Vaccine Platform Video

Video Transcript: What is the mRNA Vaccine Platform?

[DESCRIPTION]

On-screen text:

What is the mRNA Vaccine Platform? For Healthcare Professionals

[SPEECH]

Let’s take a quick look at Moderna’s mRNA platform, which forms the basis of the Moderna COVID‑19 Vaccine.

But first, please be aware of the following important information about the Moderna COVID‑19 Vaccine.

[DESCRIPTION AND SPEECH]

On-screen text and voice:

FDA has approved SPIKEVAX (COVID‑19 Vaccine, mRNA) as a two-dose primary series for the prevention of COVID‑19 in individuals ages 18 years of age and older.

The Moderna COVID‑19 Vaccine has not been approved by the FDA, but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA), to provide a two-dose primary series (0.5 mL) to individuals 18 years of age and older. Additionally, the Moderna COVID‑19 Vaccine has been authorized to provide a third primary series dose (0.5 mL) to individuals ages 18 years of age and older who have been determined to have certain kinds of immunocompromise. The EUA also authorizes a single (0.25 mL) booster dose of the Moderna COVID‑19 Vaccine at least 5 months after completing a primary series of the Moderna COVID‑19 Vaccine or SPIKEVAX to individuals 18 years of age and older. Under the EUA, the booster dose may also be administered to individuals 18 years of age or older as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID‑19 vaccine. The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the COVID‑19 EUA declaration justifying emergency use of the vaccine, unless the declaration is terminated or authorization revoked sooner.

[DESCRIPTION]

On-screen text:

FDA-approved SPIKEVAX and the EUA-authorized Moderna COVID‑19 Vaccine have the same formulation and can be used interchangeably without presenting any safety or effectiveness concerns.

For information on the authorized use of the Moderna COVID‑19 Vaccine and mandatory requirements of the EUA, please review the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf.

For information regarding SPIKEVAX, see SPIKEVAX Full Prescribing Information at https://www.modernatx.com/covid19vaccine-eua/spikevax-prescribing-information.pdf.

[DESCRIPTION]

The image of a scientific journal is displayed, with the words “Moderna”,“mRNA”, and “Est.2010” on the cover.

On-screen text:

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer the Moderna COVID‑19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID‑19 Vaccine.

[SPEECH]

The name Moderna might be new to you, but we’ve been focused on research and development of new medicines since 2010.

[DESCRIPTION]

The logos of several national and international health agencies and research organizations appear: NIH, NIAID, BARDA, Institut Pasteur, Karolinska Institutet.

[SPEECH]

Our research, including partnerships with leading health agencies and research organizations, has focused on a new class of medicines and vaccines based on messenger RNA, or mRNA.

[DESCRIPTION]

On-screen text:

FIGURE 1. THE CENTRAL DOGMA

A visual representation of DNA appears with an arrow pointing to a strand of mRNA, which has an arrow pointing to a protein.

[SPEECH]

As you know from basic biology, mRNA is used by every cell in the body to make the proteins that drive many aspects of human health and disease.

[DESCRIPTION]

The image of a vial appears. Next to it is a large image of different viruses with an X over them.

Then the image changes to a vial with an mRNA strand next to it.

The image zooms into the mRNA as a ribosome appears alongside it within a cell. The image shows the ribosome-mRNA complex producing a viral antigen.

On-screen text:

Ribosome
Nucleoside-modified mRNA
Viral Antigen

[SPEECH]

A vaccine based on mRNA does not include any virus, but instead a sequence of nucleoside-modified mRNA encoding viral antigens.

This technology helps the body itself produce the viral antigen, against which the body mounts an immune response.

[DESCRIPTION]

Everything fades except for the image of the mRNA strand.

On-screen text:

Nucleoside-modified mRNA

[SPEECH]

The mRNA is nonreplicating, and is only present in the cell transiently. It does not enter the cell nucleus or interact with DNA.

[DESCRIPTION]

The image fades out and is replaced with the image of an mRNA strand enclosed within a lipid particle.

On-screen text:

No adjuvants or preservatives

Can be stored under refrigeration up to 30 days after thawing

No dilution required

[SPEECH]

Moderna has developed lipid particles as vehicles to deliver the mRNA into cells. This lipid technology means that the Moderna COVID‑19 Vaccine does not require adjuvants or preservatives and can be stored under refrigerated conditions for up to 30 days, once it is thawed. Please check the Fact Sheet for Vaccination Providers for details on storage and handling of the Moderna COVID‑19 Vaccine.

[DESCRIPTION]

A representation of the SARS‑CoV‑2 virus appears next to the lipid particle. Then the virus changes and the mRNA changes at the same time.

[SPEECH]

All of this research into Moderna’s mRNA platform allows for an approach that can be adapted to target specific viruses, including SARS‑CoV‑2, the virus that causes COVID‑19, by placing the mRNA code for the viral target within the platform.

Please note the following important safety information for the Moderna COVID‑19 Vaccine.

[DESCRIPTION]

On-screen text:

Important Safety Information for Moderna COVID‑19 Vaccine

[DESCRIPTION AND SPEECH]

On-screen text and voice:

AUTHORIZED USE

The Moderna COVID‑19 Vaccine has not been approved by the FDA, but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA), to provide a two-dose primary series (0.5 mL) to individuals 18 years of age and older. Additionally, the Moderna COVID‑19 Vaccine has been authorized to provide a third primary series dose (0.5 mL) to individuals ages 18 years of age and older who have been determined to have certain kinds of immunocompromise. The EUA also authorizes a single (0.25 mL) booster dose of the Moderna COVID‑19 Vaccine at least 5 months after completing a primary series of the Moderna COVID‑19 Vaccine or SPIKEVAX (COVID‑19 Vaccine, mRNA) to individuals 18 years of age and older. Under the EUA, the booster dose may also be administered to individuals 18 years of age or older as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID‑19 vaccine. The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the COVID‑19 EUA declaration justifying emergency use of the vaccine, unless the declaration is terminated or authorization revoked sooner.
FDA has approved SPIKEVAX as a two-dose primary series for the prevention of COVID‑19 in individuals ages 18 years of age and older.
FDA-approved SPIKEVAX and the EUA-authorized Moderna COVID‑19 Vaccine have the same formulation and can be used interchangeably without presenting any safety or effectiveness concerns.

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer the Moderna COVID‑19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID‑19 Vaccine.

Warnings and Precautions

  • Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID‑19 Vaccine. Monitor Moderna COVID‑19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html)
  • Myocarditis and Pericarditis: Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The observed risk is higher among males under 40 years of age than among females and older males. The observed risk is highest in males 18 through 24 years of age. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).
  • Syncope (fainting): May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
  • Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the Moderna COVID‑19 Vaccine.
  • Limitations of Vaccine Effectiveness: The Moderna COVID‑19 Vaccine may not protect all vaccine recipients.

Adverse Reactions

Adverse reactions reported in clinical trials following administration of the Moderna COVID‑19 Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, erythema at the injection site, and rash.

Anaphylaxis and other severe allergic reactions, myocarditis, pericarditis, and syncope have been reported following administration of the Moderna COVID‑19 Vaccine during mass vaccination outside of clinical trials.

Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID‑19 Vaccine.

Reporting Adverse Events and Vaccine Administration Errors

The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS):

  • vaccine administration errors whether or not associated with an adverse event
  • serious adverse events (irrespective of attribution to vaccination)
  • cases of Multisystem Inflammatory Syndrome (MIS) in adults
  • cases of COVID‑19 that result in hospitalization or death

Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS, call 1-800-822-7967. Reports should include the words “Moderna COVID‑19 Vaccine EUA” in the description section of the report.

Report to ModernaTX, Inc. by calling 1-866-MODERNA (1-866-663-3762) or provide a copy of the VAERS form by faxing 1-866-599-1342 or emailing .

For more information, see the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information at https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf.

For information regarding SPIKEVAX, see SPIKEVAX Full Prescribing Information at https://www.modernatx.com/covid19vaccine-eua/spikevax-prescribing-information.pdf.

[DESCRIPTION]

The Moderna logo is displayed, along with the website ModernaTX.com.

[SPEECH]

Visit ModernaTX.com to learn more about mRNA technology.

[DESCRIPTION]

Job code is displayed on screen:

US-COV-2200038 02/2022

[END OF TRANSCRIPT]

Storage & Handling
Moderna COVID‑19 Vaccine Video

Video Transcript: Storage and Handling Moderna COVID‑19 Vaccine For Healthcare Professionals

[DESCRIPTION]

On-screen text:

Storage and Handling Moderna COVID‑19 Vaccine For Healthcare Professionals

[SPEECH]

Let’s take a quick look at some select information about the Storage and Handling of the Moderna COVID‑19 Vaccine. Please refer to the Fact Sheet for Vaccination Providers for full information on Storage, Handling, Dosing, and Administration.

But first, please be aware of the following important information about the Moderna COVID‑19 Vaccine.

[DESCRIPTION AND SPEECH]

On-screen text and voice:
FDA has approved SPIKEVAX (COVID‑19 Vaccine, mRNA) as a two-dose primary series for the prevention of COVID‑19 in individuals ages 18 years of age and older.

The Moderna COVID‑19 Vaccine has not been approved by the FDA, but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA), to provide a two-dose primary series (0.5 mL) to individuals 18 years of age and older. Additionally, the Moderna COVID‑19 Vaccine has been authorized to provide a third primary series dose (0.5 mL) to individuals ages 18 years of age and older who have been determined to have certain kinds of immunocompromise. The EUA also authorizes a single (0.25 mL) booster dose of the Moderna COVID‑19 Vaccine at least 5 months after completing a primary series of the Moderna COVID‑19 Vaccine or SPIKEVAX to individuals 18 years of age and older. Under the EUA, the booster dose may also be administered to individuals 18 years of age or older as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID‑19 vaccine. The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the COVID‑19 EUA declaration justifying emergency use of the vaccine, unless the declaration is terminated or authorization revoked sooner.

[DESCRIPTION]

On-screen text:

FDA-approved SPIKEVAX and the EUA-authorized Moderna COVID‑19 Vaccine have the same formulation and can be used interchangeably without presenting any safety or effectiveness concerns.

For information on the authorized use of the Moderna COVID‑19 Vaccine and mandatory requirements of the EUA, please review the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf.

[DESCRIPTION]

A delivery truck moves onto screen from the left and eventually moves off the screen on the right.

On-screen text:

Shipped Frozen

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer the Moderna COVID‑19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID‑19 Vaccine.

[SPEECH]

Moderna COVID‑19 Vaccine is shipped to your location frozen, using existing shipping practices.

[DESCRIPTION]

A closed carton of Moderna COVID‑19 vaccines appears with the words “Moderna COVID‑19 Vaccine” on it.

On screen text:

Frozen storage
Freezer temperature
-50° to -15° C
(-58° to 5° F)
During storage, protect from room light, and avoid exposure to direct sunlight and ultraviolet light.

[SPEECH]

Upon arrival, the Moderna COVID‑19 Vaccine can be stored frozen until the expiration date.

During storage, protect from room light, and avoid exposure to direct sunlight and ultraviolet light.

[DESCRIPTION]

The carton opens to reveal 10 vials.

[SPEECH]

Each carton contains 10 multidose vials. Vial amounts vary, with some containing 5.5 mL, and some containing 7.5 mL.

[DESCRIPTION]

The image fades. A single vial of vaccine appears.

[SPEECH]

Prior to administration, thaw one vial at a time.

For the 5.5 mL vial, thaw the vial in the refrigerator for 2 hours and 30 minutes. For the 7.5 mL vial, thaw in the refrigerator for 3 hours. In both cases, let the vial stand for 15 minutes at room temperature before administering.

[DESCRIPTION]

The vial moves to a shelf in the refrigerator

On screen text:

Thaw vial before administration

Refrigerator

  • 5.5 mL Vial: 2 hours 30 minutes
  • 7.5 mL Vial: 3 hours
  • 2°C to 8°C (36°F to 46°F)

Let vial stand at room temperature for 15 minutes before administering.

Do not refreeze once thawed.
Do not shake or dilute.

The screen splits to display the vial in the refrigerator on the left and the vial on a shelf at room temperature on the right.

On-screen text:

Room temperature

  • 5.5 mL Vial: 1 hour
  • 7.5 mL Vial: 1 hour and 30 minutes
  • 15°C to 25°C (59°F to 77°F)

[SPEECH]

Alternatively, for the 5.5 mL vial thaw at room temperature for 1 hour, or for the 7.5 mL vial 1 hour and 30 minutes. After the vial has been thawed, do not refreeze.

Primary series of 0.5 mL and booster doses of 0.25 mL may be extracted from either vial presentation.

[DESCRIPTION]

Split screen fades and an unpunctured vial appears.

On-screen text :

Unpunctured vials
Store refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days.
Store between 8° to 25°C (46° to 77°F) for up to 24 hours.
Do not refreeze once thawed.
Do not shake or dilute.

[SPEECH]

Once thawed, unpunctured vials can be stored in the refrigerator for up to 30 days.

The total storage time of an unpunctured vial after removal from refrigerated conditions should not exceed 24 hours.

[DESCRIPTION]

Next, the vial is shown punctured, implying that a needle has already entered the vial and withdrawn a dose of vaccine. Liquid in the vial decreases, which represents vaccine doses being withdrawn.

On-screen text:

For illustrative purposes only

Punctured vials
Do not shake or dilute
Do not pool excess vaccine from multiple vials

  • After first dose has been withdrawn, vial should be held between 2°C to 25°C (36°F to 77°F).
  • Record the date and time of first use on the Moderna COVID‑19 Vaccine vial label. Discard vial after 12 hours.
  • If the amount of vaccine remaining in the vial cannot provide a full dose of 0.5 mL or 0.25 mL, discard the vial and contents. Do not pool excess vaccine from multiple vials.
  • The maximum number of doses that may be extracted from either vial presentation should not exceed 20 doses. Do not puncture the vial stopper more than 20 times. If the vial stopper has been punctured 20 times, discard the vial and contents.

Do not refreeze once thawed.
Do not shake or dilute.

THAWED, UNPUNCTURED VIAL
Store refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30 days.
Unpunctured vials may be stored between 8°C to 25°C (46°F to 77°F) for up to 24 hours.
Do not refreeze.

THAWED, PUNCTURED VIAL
Punctured vial should be held between 2°C to 25°C (36°F to 77°F).
Discard vial after 12 hours.
Do not refreeze.

[DESCRIPTION]

The punctured vial moves to the right to display a side-by-side view with an unpunctured vial on the left.

[SPEECH]

After the first dose has been withdrawn, punctured vials must be discarded after 12 hours, whether they’re stored in the refrigerator or at room temperature.

Thawed vials can be handled in room light conditions.

Once thawed, never refreeze Moderna COVID‑19 Vaccine.

[DESCRIPTION]

The vials fade from view.

[SPEECH]

Please check the Fact Sheet for Vaccination Providers for full details on storage, handling, dosing, and administration of the Moderna COVID‑19 Vaccine.

[DESCRIPTION]

On-screen text:
MODERNA COVID‑19 VACCINE THAWING & STORAGE

[DESCRIPTION]

A list of four items appears. There are checkboxes next to each item, and a check mark appears in each checkbox. The four items on the list are:

On-screen text:

  • FROZEN STORAGE PRIOR TO USE
    The Moderna COVID‑19 Vaccine multiple-dose vials are stored frozen between -50°C to -15°C (-58°F to 5°F).
  • THAWING
    Thaw in refrigerated conditions between 2°C to 8°C (36°F to 46°F) for 2 hours and 30 minutes for the 5.5 mL vial, or 3 hours for the 7.5 mL vial. Let vial stand at room temperature for 15 minutes before administering. Alternatively, thaw at room temperature between 15°C to 25°C (59°F to 77°F) for 1 hour for the 5.5 mL vial, or 1 hour and 30 minutes for the 7.5 mL vial.
  • REFRIGERATED STORAGE PRIOR TO USE
    Vials can be stored refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30 days prior to first use. Do not refreeze once thawed. Unpunctured vials may be stored between 8°C to 25°C (46°F to 77°F) for up to 24 hours. Do not refreeze once thawed.
  • STORAGE AFTER FIRST PUNCTURE OF THE VACCINE VIAL
    After the first dose has been withdrawn, the vial should be held between 2°C to 25°C (36°F to 77°F). Discard vial after 12 hours. Do not refreeze.

[SPEECH]

Please note the following important safety information for the Moderna COVID‑19 Vaccine.

[DESCRIPTION]

On-screen text:
Important Safety Information for Moderna COVID‑19 Vaccine

[DESCRIPTION AND SPEECH]

On-screen text and voice:

AUTHORIZED USE

The Moderna COVID‑19 Vaccine has not been approved by the FDA, but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA), to provide a two-dose primary series (0.5 mL) to individuals 18 years of age and older. Additionally, the Moderna COVID‑19 Vaccine has been authorized to provide a third primary series dose (0.5 mL) to individuals ages 18 years of age and older who have been determined to have certain kinds of immunocompromise. The EUA also authorizes a single (0.25 mL) booster dose of the Moderna COVID‑19 Vaccine at least 5 months after completing a primary series of the Moderna COVID‑19 Vaccine or SPIKEVAX (COVID‑19 Vaccine, mRNA) to individuals 18 years of age and older. Under the EUA, the booster dose may also be administered to individuals 18 years of age or older as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID‑19 vaccine. The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the COVID‑19 EUA declaration justifying emergency use of the vaccine, unless the declaration is terminated or authorization revoked sooner.

FDA has approved SPIKEVAX as a two-dose primary series for the prevention of COVID‑19 in individuals ages 18 years of age and older.

FDA-approved SPIKEVAX and the EUA-authorized Moderna COVID‑19 Vaccine have the same formulation and can be used interchangeably without presenting any safety or effectiveness concerns.

IMPORTANT SAFETY INFORMATION

Contraindications
Do not administer the Moderna COVID‑19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID‑19 Vaccine.

Warnings and Precautions

  • Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID‑19 Vaccine. Monitor Moderna COVID‑19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).
  • Myocarditis and Pericarditis: Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The observed risk is higher among males under 40 years of age than among females and older males. The observed risk is highest in males 18 through 24 years of age. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).
  • Syncope (fainting): May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
  • Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the Moderna COVID‑19 Vaccine.
  • Limitations of Vaccine Effectiveness: The Moderna COVID‑19 Vaccine may not protect all vaccine recipients.

Adverse Reactions

Adverse reactions reported in a clinical trial following administration of the Moderna COVID‑19 Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, erythema at the injection site, and rash.

Anaphylaxis and other severe allergic reactions, myocarditis, pericarditis, and syncope have been reported following administration of the Moderna COVID‑19 Vaccine during mass vaccination outside of clinical trials.

Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID‑19 Vaccine.

Reporting Adverse Events and Vaccine Administration Errors

The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS):

  • vaccine administration errors whether or not associated with an adverse event
  • serious adverse events (irrespective of attribution to vaccination)
  • cases of Multisystem Inflammatory Syndrome (MIS) in adults
  • cases of COVID‑19 that result in hospitalization or death

Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS, call 1‑800‑822‑7967. Reports should include the words “Moderna COVID‑19 Vaccine EUA” in the description section of the report.

Report to ModernaTX, Inc. by calling 1-866-MODERNA (1‑866‑663‑3762) or provide a copy of the VAERS form by faxing 1-866-599-1342 or emailing ModernaPV@modernatx.com.

For more information, see the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information at https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf.

For information regarding SPIKEVAX, see SPIKEVAX Full Prescribing Information at https://www.modernatx.com/covid19vaccine-eua/spikevax-prescribing-information.pdf.

[DESCRIPTION]

The Moderna logo is displayed, along with the URL ModernaTX.com.

[SPEECH]

Get more information about Moderna at ModernaTX.com.

[DESCRIPTION]

Job code is displayed on screen:

US-COV-2200041 02/2022

[END OF TRANSCRIPT]

Vial Puncture
Moderna COVID‑19 Vaccine Video

How to Swirl Vials of the Moderna COVID-19 Vaccine Prior to Administration

Moderna COVID-19 Vaccine Primary vs Booster Dose

Administration Blue Cap - 0.25mL Dose

Administration Blue Cap - 0.50mL Dose